Loading clinical trials...
Loading clinical trials...
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ascendis Pharma Endocrinology Division A/S
NCT07333521 · Isolated Non-acquired Growth Hormone Deficiency
NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more
NCT00227253 · Chromosome Aberrations, Growth Hormone Deficiency, and more
NCT01604395 · Growth Hormone Deficiency, Turner Syndrome, and more
NCT06109935 · Growth Hormone Deficiency in Children
Ascendis Investigational Site
Phoenix, Arizona
Ascendis Investigational Site
Orange, California
Ascendis Investigational Site
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions